Coombe Bender & Co LLC Sells 2,242 Shares of Bristol-Myers Squibb (NYSE:BMY)

Coombe Bender & Co LLC lessened its holdings in Bristol-Myers Squibb (NYSE:BMY) by 7.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,879 shares of the biopharmaceutical company’s stock after selling 2,242 shares during the quarter. Coombe Bender & Co LLC’s holdings in Bristol-Myers Squibb were worth $1,379,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in BMY. Fisher Asset Management LLC raised its holdings in Bristol-Myers Squibb by 130.7% during the 4th quarter. Fisher Asset Management LLC now owns 224,537 shares of the biopharmaceutical company’s stock worth $11,521,000 after purchasing an additional 127,228 shares during the last quarter. Great Valley Advisor Group Inc. lifted its holdings in Bristol-Myers Squibb by 197.3% in the fourth quarter. Great Valley Advisor Group Inc. now owns 46,311 shares of the biopharmaceutical company’s stock valued at $2,376,000 after buying an additional 30,734 shares during the period. Searle & CO. lifted its holdings in Bristol-Myers Squibb by 11.9% in the fourth quarter. Searle & CO. now owns 104,081 shares of the biopharmaceutical company’s stock valued at $5,340,000 after buying an additional 11,048 shares during the period. Concord Wealth Partners grew its holdings in Bristol-Myers Squibb by 41.7% during the 4th quarter. Concord Wealth Partners now owns 30,639 shares of the biopharmaceutical company’s stock worth $1,572,000 after acquiring an additional 9,020 shares during the period. Finally, Triumph Capital Management raised its position in shares of Bristol-Myers Squibb by 166.1% in the 4th quarter. Triumph Capital Management now owns 13,787 shares of the biopharmaceutical company’s stock worth $707,000 after acquiring an additional 8,605 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on BMY. BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Bank of America cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY traded down $0.22 during trading on Thursday, hitting $43.99. 7,134,346 shares of the company were exchanged, compared to its average volume of 15,853,430. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The company has a market cap of $89.17 billion, a PE ratio of -14.15, a P/E/G ratio of 14.70 and a beta of 0.45. Bristol-Myers Squibb has a 52-week low of $43.33 and a 52-week high of $69.10. The stock has a 50 day moving average of $50.67 and a 200 day moving average of $50.89.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.05 earnings per share. As a group, equities research analysts predict that Bristol-Myers Squibb will post 0.6 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.46%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.